Benzinga | Sep 30, 2020 07:28AM EDT

Benchmark Initiates Coverage On Neurocrine Biosciences with Hold Rating

Benchmark analyst Aydin Huseynov initiates coverage on Neurocrine Biosciences (NASDAQ:NBIX) with a Hold rating.